Loading, Please Wait...
SAN FRANCISCO, CA--(Marketwired - Feb 24, 2016) - The gastrointestinal therapeutics in Asia-Pacific markets is expected to grow during 2012 to 2019 (forecast period). The market expects to capitalize on growing gastronomic disorders like Crohn's Disease (CD), Irritable Bowel Syndrome (IBS), and Ulcerative Colitis (UC).
The market was estimated to be worth USD 6.8 billion in 2012. It is expected to experience a downward growth rate of 0.3% during the forecast period. Patent expiry on major gastrointestinal drugs is expected to hamper market growth. The market will maintain its growth on account of prevailing gastrointestinal (GI) diseases and tools to detect them early.
Browse Full Research Report With TOC On "Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need" at: http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need
IBS had a market value of USD 727 million in 2012 and expects to grow at a 14.4% CAGR over the next 7 years. Similarly, UC had a market value of USD 2.2 billion in 2012 and CD was worth USD 3.8 billion in the same year. UC is predicted to grow at a 6% CAGR and CD at a 7.5% CAGR over the forecast period.
Amitiza, Humira, Remicade, Simponi, Cimzia, and Tysabri are products of the gastrointestinal therapeutics market in Asia-Pacific. Other drugs yet to enter the market are GSK-1605786, MLN0002, and EMD-61753.
Countries covered by the market in Asia-Pacific are India, Japan, China, and Australia. Japan will experience a 4% CAGR during the forecast period.
Browse related reports by Radiant Insights:
About Radiant Insight
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.